InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
0.8070
-0.0081 (-0.99%)
At close: Aug 8, 2025, 4:00 PM
0.8165
+0.0095 (1.18%)
After-hours: Aug 8, 2025, 7:53 PM EDT

Company Description

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.

The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases.

Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS.

It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V.

and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

InflaRx N.V.
InflaRx logo
CountryGermany
Founded2007
IPO DateNov 8, 2017
IndustryBiotechnology
SectorHealthcare
Employees74
CEONiels Riedemann

Contact Details

Address:
Winzerlaer Str. 2
Jena, 07745
Germany
Phone49 3641 508 180
Websiteinflarx.de

Stock Details

Ticker SymbolIFRX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyEUR
CIK Code0001708688
CUSIP NumberN44821101
ISIN NumberNL0012661870
SIC Code2834

Key Executives

NamePosition
Dr. Niels C. Riedemann M.D., Ph.D.Co-Founder, Chief Executive Officer and Executive Director
Prof. Renfeng Guo M.D.Co-Founder, Chief Scientific Officer and Executive Director
Dr. Thomas Taapken Ph.D.Chief Financial Officer
Derval O'CarrollSenior Vice President and Global Head of Regulatory Affairs and Compliance
Dr. Camilla Chong M.D.Chief Medical Officer
Jan Medina CFAHead of Investor Relations and Vice President
Christian SchmidVice President and Head of Legal Affairs and General Counsel
Nicole BertschSenior Director and Head of Human Resources
Dr. Maria Habel PH.D.Vice President, Head of Preclinical Research & Development and QC
Dr. Bruce P. Burnett Ph.D.Vice President and Head of Medical Affairs

Latest SEC Filings

DateTypeTitle
Aug 7, 20256-KReport of foreign issuer
Jul 14, 20256-KReport of foreign issuer
Jun 27, 20256-KReport of foreign issuer
May 28, 20256-KReport of foreign issuer
May 7, 20256-KReport of foreign issuer
Apr 24, 20256-KReport of foreign issuer
Apr 3, 20256-KReport of foreign issuer
Mar 20, 202520-FAnnual and transition report of foreign private issuers
Mar 20, 20256-KReport of foreign issuer
Feb 18, 20256-KReport of foreign issuer